- Home
- DNP vs PTGX Comparison
DNP vs PTGX Comparison
Compare DNP & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- PTGX
- Stock Information
- Founded
- DNP 1986
- PTGX 2006
- Country
- DNP United States
- PTGX United States
- Employees
- DNP N/A
- PTGX N/A
- Industry
- DNP Investment Managers
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- DNP Finance
- PTGX Health Care
- Exchange
- DNP Nasdaq
- PTGX Nasdaq
- Market Cap
- DNP 3.7B
- PTGX 3.7B
- IPO Year
- DNP N/A
- PTGX 2016
- Fundamental
- Price
- DNP $9.99
- PTGX $59.55
- Analyst Decision
- DNP
- PTGX Strong Buy
- Analyst Count
- DNP 0
- PTGX 8
- Target Price
- DNP N/A
- PTGX $70.13
- AVG Volume (30 Days)
- DNP 479.6K
- PTGX 872.6K
- Earning Date
- DNP 01-01-0001
- PTGX 11-06-2025
- Dividend Yield
- DNP 7.88%
- PTGX N/A
- EPS Growth
- DNP N/A
- PTGX N/A
- EPS
- DNP 2.30
- PTGX 0.80
- Revenue
- DNP $154,887,179.00
- PTGX $209,180,000.00
- Revenue This Year
- DNP N/A
- PTGX N/A
- Revenue Next Year
- DNP N/A
- PTGX $185.11
- P/E Ratio
- DNP $4.26
- PTGX $74.07
- Revenue Growth
- DNP 3.30
- PTGX N/A
- 52 Week Low
- DNP $8.69
- PTGX $33.31
- 52 Week High
- DNP $10.04
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- DNP 60.01
- PTGX 56.62
- Support Level
- DNP $9.92
- PTGX $54.50
- Resistance Level
- DNP $10.02
- PTGX $61.04
- Average True Range (ATR)
- DNP 0.07
- PTGX 2.67
- MACD
- DNP 0.01
- PTGX -0.03
- Stochastic Oscillator
- DNP 85.42
- PTGX 68.34
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.